The Board granted Hospira a mixed result in its numerous challenges to Genentech’s patents directed to different aspects of Genentech’s trastuzumab product:

The Board instituted IPR of U.S. Patent No. 7,371,379 (IPR2017-00805), U.S. Patent No. 6,627,196 (IPR2017-00804), and U.S. Patent No. 7,892,549 (IPR2017-00737).  The Board denied institution of IPR of U.S. Patent 7,892,549 (IPR2017-00739) and U.S. Patent 7,846,441 (IPR2017-00731).